A phase I trial of LY573636 administered as a 24-hour continuous infusion on day 1 of a 28-day cycle in patients with refractory solid tumors
Phase of Trial: Phase I
Latest Information Update: 04 Jul 2006
At a glance
- Drugs Tasisulam (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 04 Jul 2006 New trial record.